NCT07166497Completed
Evaluation of the Effect of the Product RV4660C CY0203 on Clinical, Biometrological and Biological Parameters in Adults With Mild to Moderate Atopic Dermatitis, an Exploratory Study
Source: ClinicalTrials.gov · Last updated 10 Sept 2025
Brief summary (registry, in English)
In this exploratory study, we assessed the efficacy of a cosmetic product in adults suffering from mild to moderate atopic dermatitis. This exploratory study has been conducted as a monocentric non randomized study. To perform this clinical study, 21 non menopausal women, aged from 18 years and older, suffering from mild to moderate atopic dermatitis were enrolled. The subjects applied the investigational product once a day, in the evening on the whole body/ off face for up to 31 days. 4 visits were planned: * Visit 1 - Day 1 - Inclusion visit * Visit 2 - Day 8 - Intermediate visit * Visit 3 - Day 29 (± 3 days) - Intermediate visit * Visit 4 - Day 36 (± 3 days) - End of study visit
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 21 (actual)
- First submitted
- 3 Sept 2025
- Start date
- 30 Oct 2023
- Primary completion date
- 22 Dec 2023
- Lead sponsor
- Pierre Fabre Dermo Cosmetique
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07166497
What you commit to
- Study type: Observational
- Participants enrolled: 21
- From 30 Oct 2023 to the primary completion date, 22 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Main inclusion criteria :
- Woman 18 years or older
- Non-menopausal woman
- Subject with phototype I, II, III, IV as classified by Fitzpatrick
- Subject with AD according to "The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis"
- Mild to moderate AD with SCORAD (SCORing Atopic Dermatitis) between 20 and 40 inclusive
- Subject who had at least 1 inflammatory AD flare-up in target areas in the year prior to inclusion visit
- Subject with at least one measuring target area on each upper or lower limb and defined as a typical AD flare-up area in the opinion of the subject
- Subject with at least one target area on each upper or lower limb with the following SCORAD target signs (between 3 and 18):
- Erythema ≥ 1
- Xerosis \> 1
- Subject with pruritus intensity ≥ 3 on SCORAD analog visual scale (VAS)
- Main non-inclusion criteria:
- Subject with superinfected AD
- Subject with a known history of allergy or intolerance to the components of the study product
- Subject with a dermatological condition other than AD, or characteristics (for example, tattoo) on the study areas, likely to interfere with the study evaluations according to the investigator's opinion
- Subject with another dermatological condition, acute or chronic pathology, or history of pathology, likely to interfere with study evaluations, or considered dangerous to the subject or incompatible with study requirements, in the opinion of the investigator
- Topical or oral treatment established or modified during the previous weeks or planned to be established or modified during the study, liable to interfere with the evaluation of the efficacy or cutaneous tolerance of the investigational product according to the investigator's assessment
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Skin Research Center Coordinator of this site? Confirm its status | Toulouse | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.